Sodium Pentosan Polysulfate Resulted in Cartilage Improvement in Knee Osteoarthritis - An Open Clinical Trial

Kenji Kumagai; Susumu Shirabe; Noriaki Miyata; Masakazu Murata; Atsushi Yamauchi; Yasuhumi Kataoka; Masami Niwa


BMC Clin Pharmacol. 2010;10:1-24. 

In This Article


Osteoarthritis (OA) is the most widespread joint disease affecting the elderly population.[1] Non-steroidal anti-inflammatory drugs (NSAIDs), supplements of chondroitin sulfate and/or glycosaminoglycans are prescribed as non-operative treatments. Recently, intraarticular injection of hyaluronic acid (HA) has become a common treatment. Within the last few decades, the concept of disease-modifying osteoarthritis drugs (DMOADs) has been explored as an alternative therapeutic treatment for OA.

From the results of previous in vitro and animal model studies, we have proposed that the spectrum of pharmacological activities exhibited by pentosan polysulfate sodium (Pentosan) would qualify it as DMOADs. However, there is little human clinical evidence to support this proposition. The aim of this study is to assess the clinical effectiveness, functional outcome, safety, and patient satisfaction of a series of subcutaneous injections of pentosan in patients with symptomatic primary OA of the knee. Parts of this study were presented at the International Society of Orthopedic Surgery and Traumatology (SICOT), in Hong Kong, China in 2008 and at the OsteoArthritis Research Society International (OARSI) World Congress on Osteoarthritis, in Rome, Italy in 2008.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.